Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Growth Small Cap
  • Asset Class: Equity
  • Geographic Focus: U.S.

Dreyfus/The Boston Company Small Cap Growth Fund

+ Add to Watchlist

SSYGX:US

38.22 USD 0.34 0.90%

As of 09:29:30 ET on 03/05/2015.

Snapshot for Dreyfus/The Boston Company Small Cap Growth Fund (SSYGX)

Year To Date: +5.06% 3-Month: +6.77% 3-Year: - 52-Week Range: 32.72 - 39.68
1-Month: +3.86% 1-Year: +2.21% 5-Year: - Beta vs RUO: -

Mutual Fund Chart for SSYGX

No chart data available.
  • SSYGX:US 38.22
  • 1M
  • 1Y
Interactive SSYGX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for SSYGX

Dreyfus/The Boston Company Small Cap Growth Fund is an open-end fund incorporated in the USA. The Fund's objective seeks long-term growth of capital. The Fund invests all of its investible assets in a Standish master portfolio which invests, under normal circumstances, at least 80% of net assets in equity securities of small cap U.S. companies.

Inception Date: 07-01-2013 Telephone: 1-800-346-8893 Domestic
Managers: TODD W WAKEFIELD / ROBERT ZEUTHEN
Web Site: www.dreyfus.com

Fundamentals for SSYGX

NAV (on 2015-03-05) 38.22
Assets (M) (on 2015-03-05) 28.86
Fund Leveraged N
Minimum Investment 1,000,000.00
Minimum Subsequent Investment 0.00

Dividends for SSYGX

No dividends reported

Fees & Expenses for SSYGX

Front Load 0.00
Back Load 0.00
Current Mgmt Fee 0.80
Redemption Fee -
12b1 Fee -
Expense Ratio 0.95

Top Fund Holdings for SSYGX

Filing Date: 11/30/2014
Name Position Value % of Total
Nektar Therapeutics 56,480 941,522 1.914%
Watsco Inc 9,120 925,680 1.882%
Anacor Pharmaceuticals Inc 25,718 886,757 1.803%
WuXi PharmaTech Cayman Inc 24,510 840,938 1.710%
BioDelivery Sciences Internati 54,540 837,189 1.702%
LogMeIn Inc 16,250 821,763 1.671%
RE/MAX Holdings Inc 24,540 820,863 1.669%
Pacira Pharmaceuticals Inc/DE 8,463 794,930 1.616%
Sonus Networks Inc 42,082 778,517 1.583%
Align Technology Inc 13,500 768,150 1.562%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil